Review literature: (Simon and Stille, 1997).
Co-trimoxazole is an antibiotic with a fixed combination of trimethoprim (dihydrofolate reductase inhibitor) and sulfamethoxazole (sulfonamide).
Co-trimoxazole is bactericidal due to the double inhibition of bacterial folic acid synthesis.
Bacteria causing urinary tract infection such as E. coli, Enterococci, Mycoplasma, Klebsiella, Serratia, Enterobacter (KES group), but with increasing resistance rates.
Treatment or prevention of urinary tract infection.
Skin rash, rarely severe skin reactions (Stevens-Johnson and Lyell's syndrome).
Exacerbation of renal failure (reversible).
Bone marrow depression in case of long-term therapy, rarely agranulocytosis.
Co-trimoxazole enhances the effect of phenytoin and sulfonylureas. Increased toxicity of cyclosporine, barbiturates, p-aminosalicylic acid and methotrexate.
The ratio between trimethoprim and sulfamethoxazole is 1:5. The dosage for adults is 480 mg (80 mg trimethoprim and 400 mg sulfamethoxazole) 1-0-1 p.o. to 960 mg p.o. 1-0-1. The dosage for children is 24 mg/kg p.o. co-trimoxazole 1-0-1.
In uncomplicated acute cystitis of women, co-trimoxazole is given for 3 days. In any other urinary tract infection, the recommended treatment duration is at least 7 days.
| Urologic drugs | Index | Bladder infection |
You did not find what you are looking for?
Search this site with Google:
Deutsche Version: Cotrimoxazol
Last update
Dr. med. Dirk Manski
man...@urologielehrbuch.de